Back to News
Feb 17, 2026 4:01 PM

Immortal Dragons Bet on 3D Biofabrication to Address Organ Failure

SINGAPORE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Immortal Dragons, a Singapore-based longevity fund, has announced its further support for 3D biofabrication as a primary technical solution for age-related organ failure. The move signals a shift in the biotechnology investment landscape toward regenerative "replacement" models designed to intervene before the onset of chronic disease.

The Catalyst: 3D Biofabrication

In a recent technical discussion on the Inside Precision Medicine podcast, Immortal Dragons founder Boyang Wang detailed the firm's focus on 3D biofabrication. This technology utilizes "bio-inks"—living cells integrated with biocompatible materials, to create functional tissue.

The sector currently targets the $12 billion vascular ...